Mesenchymal stromal cells may enhance metastasis of neuroblastoma via SDF-1/CXCR4 and SDF-1/CXCR7 signaling

Cancer Letters

Volumn 312, Issue 1, 2011, Pages 1-10

  Ma, Ming ^a   Ye, Jie Yu ^a   Deng, Ruixia ^a   Dee, Cathleen Michelle ^a   Chan, Godfrey Chi Fung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CXCR4; CXCR7; MSCs; Neuroblastoma; SDF 1

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; PLERIXAFOR; SHORT HAIRPIN RNA; STROMAL CELL DERIVED FACTOR 1;

ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CANCER INVASION; CELL ADHESION; CELL FUNCTION; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MESENCHYMAL STROMAL CELL; METASTASIS; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CXCL12; CHEMOTAXIS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MESENCHYMAL STEM CELLS; NEOPLASM METASTASIS; NEUROBLASTOMA; RECEPTORS, CXCR; RECEPTORS, CXCR4; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 80053335731     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.06.028     Document Type: Article

References (38)

1. Brodeur G.M., Castleberry R.P. Neuroblastoma. Principles and Practice of Pediatric Oncology 1997, 761-797. Lippincott-Raven, Philadelphia. P.A. Pizzo, D.G. Poplack (Eds.).
2. Chan G.C.F., Shing M.M.K., Luk C.W., Lee A.C.W., Ling S.C. Outcome of using stratified treatment approach based on INSS Staging in childhood neuroblastoma: the Hong Kong experience. Pediatric Blood & Cancer 2005, 45:533-534.
3. Esiashvili N., Anderson C., Katzenstein H.M. Neuroblastoma. Current Problems in Cancer 2009, 33:333-360.
4. Cheung I.Y., Feng Y., Gerald W., Cheung N.K.V. Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma. Clinical Cancer Research 2008, 14:7020-7027.
5. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F.C., Krause D.S., Deans R.J., Keating A., Prockop D.J., Horwitz E.M. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
6. Oswald J., Boxberger S., Jorgensen B., Feldmann S., Ehninger G., Bornhauser M., Werner C. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004, 22:377-384.
7. Bielby R., Jones E., McGonagle D. The role of mesenchymal stem cells in maintenance and repair of bone. Injury 2007, 38:S26-S32.
8. Majumdar M.K., Thiede M.A., Haynesworth S.E., Bruder S.P., Gerson S.L. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. Journal of Hematotherapy & Stem Cell Research 2000, 9:841-848.
9. Kuhn N.Z., Tuan R.S. Regulation of stemness and stem cell niche of mesenchymal stem cells: implications in tumorigenesis and metastasis. Journal of Cellular Physiology 2010, 222:268-277.
10. Chan W.K., Lau A.S.Y., Li J.C.B., Law H.K.W., Lau Y.L., Chan G.C.F. MHC expression kinetics and immunogenicity of mesenchymal stromal cells after short-term IFN-gamma challenge. Experimental Hematology 2008, 36:1545-1555.
11. Tso G.H.W., Law H.K.W., Tu W.W., Chan G.C.F., Lau Y.L. Phagocytosis of apoptotic cells modulates mesenchymal stem cells osteogenic differentiation to enhance IL-17 and RANKL expression on CD4+ T cells. Stem Cells 2010, 28:939-954.
12. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., Richardson A.L., Polyak K., Tubo R., Weinberg R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
13. Djouad F., Plence P., Bony C., Tropel P., Apparailly F., Sany J., Noel D., Jorgensen C. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003, 102:3837-3844.
14. De Palma M., Venneri M.A., Galli R., Sergi L.S., Politi L.S., Sampaolesi M., Naldini L. Tie2 identifies a hematopoietic monocytes required for tumor lineage of proangiogenic vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8:211-226.
15. Sohara Y., Shimada H., Minkin C., Erdreich-Epstein A., Nolta J.A., DeClerck Y.A. Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. Cancer Research 2005, 65:1129-1135.
16. Ponomaryov T., Peled A., Petit I., Taichman R.S., Habler L., Sandbank J., Arenzana-Seisdedos F., Magerus A., Caruz A., Fujii N., Nagler A., Lahav M., Szyper-Kravitz M., Zipori D., Lapidot T. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. Journal of Clinical Investigation 2000, 106:1331-1339.
17. Aiuti A., Cipponi A., Tavian M., Arcelloni C., Zappone E., Ficara F., Paroni R., Hoxie J., Peault B., Bordignon C. Expression of CXCR4, the receptor for SDF-1/PBSF, on adult and fetal human CD34+ cells. Blood 1997, 90:1142.
18. Ma Q., Jones D., Springer T.A. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 1999, 10:463-471.
19. Gross N., Meier R. Chemokines in neuroectodermal cancers: the crucial growth signal from the soil. Seminars in Cancer Biology 2009, 19:103-110.
20. Mantovani A., Savino B., Locati M., Zammataro L., Allavena P., Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine & Growth Factor Reviews 2010, 21:27-39.
21. Russell H.V., Hicks J., Okcu M.F., Nuchtern J.G. CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. Journal of Pediatric Surgery 2004, 39:1506-1511.
22. Zhang L.B., Yegery H., Das B., Irwin M.S., Baruchel S. Tissue microenvironment modulates CXCR4 expression and tumor metastasis in neuroblastoma. Neoplasia 2007, 9:36-46.
23. Airoldi I., Raffaghello L., Piovan E., Cocco C., Carlini B., Amadori A., Corrias M.V., Pistoia V. CXCL12 does not attract CXCR4(+) human metastatic neuroblastoma cells: clinical implications. Clinical Cancer Research 2006, 12:77-82.
24. Meier R., Muhlethaler-Mottet A., Flahaut M., Coulon A., Fusco C., Louache F., Auderset K., Bourloud K.B., Daudigeos E., Ruegg C., Vassal G., Gross N., Joseph J.M. The Chemokine receptor CXCR4 strongly promotes neuroblastoma primary tumour and metastatic growth, but not invasion. Plos One 2007, 2.
25. Balabanian K., Lagane B., Infantino S., Chow K.Y.C., Harriague J., Moepps B., Arenzana-Seisdedos F., Thelen M., Bachelerie F. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. Journal of Biological Chemistry 2005, 280:35760-35766.
26. Broxmeyer H.E., Orschell C.M., Clapp D.W., Hangoc G., Cooper S., Plett P.A., Liles W.C., Li X.X., Graham-Evans B., Campbell T.B., Calandra G., Bridger G., Dale D.C., Srour E.F. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. Journal of Experimental Medicine 2005, 201:1307-1318.
27. Devine S.M., Flomenberg N., Vesole D.H., Liesveld J., Weisdorf D., Badel K., Calandra G., DiPersio J.F. Rapid mobilization of CD34+cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. Journal of Clinical Oncology 2004, 22:1095-1102.
28. Smith M.C.P., Luker K.E., Garbow J.R., Prior J.L., Jackson E., Piwnica-Worms D., Luker G.D. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Research 2004, 64:8604-8612.
29. Kioi M., Vogel H., Schultz G., Hoffman R.M., Harsh G.R., Brown J.M. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. Journal of Clinical Investigation 2010, 120:694-705.
30. Kalatskaya I., Berchiche Y.A., Gravel S., Limberg B.J., Rosenbaum J.S., Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Molecular Pharmacology 2009, 75:1240-1247.
31. Li J., Law H.K.W., Lau Y.L., Chan G.C.F. Differential damage and recovery of human mesenchymal stem cells after exposure to chemotherapeutic agents. British Journal of Haematology 2004, 127:326-334.
32. Mihara K., Imai C., Coustan-Smith E., Dome J.S., Dominici M., Vanin E., Campana D. Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. British Journal of Haematology 2003, 120:846-849.
33. Burns J.M., Summers B.C., Wang Y., Melikian A., Berahovich R., Miao Z.H., Penfold M.E.T., Sunshine M.J., Littman D.R., Kuo C.J., Wei K., McMaster B.E., Wright K., Howard M.C., Schall T.J. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. Journal of Experimental Medicine 2006, 203:2201-2213.
34. Banisadr G., Dicou E., Berbar T., Rostene W., Lombet A., Haour F. Characterization and visualization of I-125 stromal cell-derived factor-1 alpha binding to CXCR4 receptors in rat brain and human neuroblastoma cells. Journal of Neuroimmunology 2000, 110:151-160.
35. Hatse S., Bridger G., de Clercq E., Schols D. X4 HIV-1 induces neuroblastoma cell death by interference with CXCL12/CXCR4 interaction. Cellular and Molecular Biology (Noisy-le-grand) 2003, 49:OL443-OL452. (Online Pub).
36. Nevo I., Sagi-Assif O., Meshel T., Ben-Baruch A., Johrer K., Greil R., Trejo L.E.L., Kharenko O., Feinmesser M., Yron I., Witz I.P. The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells. Cancer Letters 2009, 273:127-139.
37. Airoldi I., Cocco C., Morandi F., Prigione I., Pistoia V. CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow. Cancer Immunology Immunotherapy 2008, 57:541-548.
38. Goldberg-Bittman L., Sagi-Assif O., Meshel T., Nevo I., Levy-Nissenbaum O., Yron I., Witz I.P., Ben-Baruch A. Cellular characteristics of neuroblastoma cells: regulation by the ELR-CXC chemokine CXCL10 and expression of a CXCR3-like receptor. Cytokine 2005, 29:105-117.